Screener
Bicara Therapeutics BCAX Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The source filing: Bicara Therapeutics’s 10-Q, filed May 11, 2026.
- Filed
- May 11, 2026, 4:03 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-033429
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Financing activities: | ||
| Proceeds from issuance on common stock and accompanying pre-funded warrants, net of issuance costs | 161,763 | — |
| Proceeds from exercise of options | 1,582 | 460 |
| Net cash provided by financing activities | 163,345 | 460 |
| Net (decrease)/increase in cash and cash equivalents | 226,777 | (27,646) |
| Cash and cash equivalents at beginning of period | 96,685 | 489,711 |
| Cash and cash equivalents at end of period | $323,462 | $462,065 |
| Supplemental disclosure of cash flow information: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Bicara Therapeutics's financing cash flow?
- Bicara Therapeutics (BCAX) reported financing cash flow of $163.35M in Q1 2026.
- How has Bicara Therapeutics's financing cash flow changed year-over-year?
- Bicara Therapeutics's financing cash flow increased by 35409.8% year-over-year, from $460K to $163.35M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.
Ask your AI about Bicara Therapeutics's financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude